ADX-2191
ADX-2191-RP-001
Phase 2 small_molecule completed
Quick answer
ADX-2191 for Retinitis Pigmentosa is a Phase 2 program (small_molecule) at Aldeyra Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Aldeyra Therapeutics
- Indication
- Retinitis Pigmentosa
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed